<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224911</url>
  </required_header>
  <id_info>
    <org_study_id>14-000409</org_study_id>
    <secondary_id>JCCCID436</secondary_id>
    <secondary_id>NCI-2015-01487</secondary_id>
    <nct_id>NCT02224911</nct_id>
  </id_info>
  <brief_title>Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer</brief_title>
  <acronym>LITT</acronym>
  <official_title>Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, feasibility/exploratory study to evaluate the safety of laser interstitial&#xD;
      thermal therapy (LITT) using Visualase in the focal treatment of localized prostate cancer as&#xD;
      well as to gather data for the design of future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 11, 2014</start_date>
  <completion_date type="Actual">October 21, 2019</completion_date>
  <primary_completion_date type="Actual">October 21, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of prostate cancer in the MRI target area as measure of efficacy.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Laser Interstitial Thermal Therapy</arm_group_label>
    <description>This is a minimally invasive procedure for focal treatment of prostate cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser Interstitial Thermal Therapy</intervention_name>
    <arm_group_label>Laser Interstitial Thermal Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Men, 40 to 85 years of age, recently diagnosed with prostate cancer using the MRI fusion&#xD;
        technology.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with initial presentation of organ confined prostate cancer (clinical stage ≤&#xD;
             T2b)&#xD;
&#xD;
               -  Negative metastatic workup with bone scan and CT abdomen/pelvis, within 6 months&#xD;
                  of study treatment, if indicated by PSA &gt;10&#xD;
&#xD;
               -  Age 40 years to 85 years of age&#xD;
&#xD;
               -  Multi-parametric MRI at UCLA within 6 months of study treatment, demonstrating a&#xD;
&#xD;
                    -  Region of interest (ROI) of MRI suspicion level 3 or higher&#xD;
&#xD;
                    -  ROI located proximal to the external sphincter by a margin of at least 2 cm&#xD;
&#xD;
               -  Transrectal ultrasound-guided biopsy with ≥ 10 systematic biopsy cores and ≥ 2&#xD;
                  MRI-ultrasound fusion targeted biopsy cores from above MRI-derived ROI&#xD;
&#xD;
                    -  Histologically-confirmed adenocarcinoma from targeted biopsy cores (≥ 2&#xD;
                       cores)&#xD;
&#xD;
                    -  Overall Gleason score not to exceed 3+4&#xD;
&#xD;
               -  Subjects desire focal therapy and declined conventional treatment (active&#xD;
                  surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone&#xD;
                  therapy)&#xD;
&#xD;
               -  Signed informed consent for the LITT treatment through the 12 month follow up&#xD;
                  visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant cancer outside of MRI target (ROI) area, defined as Gleason score &gt;&#xD;
             3+4&#xD;
&#xD;
          -  &lt; 10 years life expectancy&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) criteria of IV or higher&#xD;
&#xD;
          -  Unfit for conscious sedation anesthesia&#xD;
&#xD;
          -  Active bleeding disorder as determined by abnormal prothrombin time, partial&#xD;
             thromboplastin time, INR or platelet count (as determined by institutional lab&#xD;
             parameters) at the time of screening&#xD;
&#xD;
          -  Use of coumadin or any other anticoagulant, unless anticoagulation can be temporarily&#xD;
             reversed or stopped for a window of at least 7 days peri-procedure&#xD;
&#xD;
          -  Active urinary tract infection&#xD;
&#xD;
          -  Prostate abscess, chronic or acute prostatitis, or neurogenic bladder&#xD;
&#xD;
          -  Any prior treatment for prostate cancer&#xD;
&#xD;
               -  Radical prostatectomy&#xD;
&#xD;
               -  Radiation therapy (external beam or brachytherapy)&#xD;
&#xD;
               -  Cryotherapy&#xD;
&#xD;
               -  High intensity focused ultrasound treatment&#xD;
&#xD;
               -  Photodynamic therapy&#xD;
&#xD;
               -  Androgen deprivation therapy&#xD;
&#xD;
          -  Prior prostate, bladder neck, or urethral stricture surgery&#xD;
&#xD;
               -  Any prostate debulking procedure, including: transurethral resection of prostate,&#xD;
                  photovaporization, or electrovaporization&#xD;
&#xD;
               -  Transurethral incision of bladder neck&#xD;
&#xD;
               -  Urethral stricture dilation or reconstruction&#xD;
&#xD;
          -  Any current 5-alpha reductase inhibitors (history of use ≥ 6 months prior to MRI is&#xD;
             acceptable)&#xD;
&#xD;
          -  Prior significant rectal surgery (hemorrhoidectomy is acceptable)&#xD;
&#xD;
          -  Rectal fissure, fibrosis, stenosis, or other anatomic abnormality precluding insertion&#xD;
             of transrectal device&#xD;
&#xD;
          -  History of inflammatory bowel disease&#xD;
&#xD;
          -  Urinary tract or rectal fistula&#xD;
&#xD;
          -  Any contraindication to MRI (contrast allergy severe claustrophobia, MRI-incompatible&#xD;
             prosthesis)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pantuck Alan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Raman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.</citation>
    <PMID>23335087</PMID>
  </reference>
  <reference>
    <citation>Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007 Dec;178(6):2359-64; discussion 2364-5. Epub 2007 Oct 22.</citation>
    <PMID>17936806</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>focal therapy</keyword>
  <keyword>prostate cancer treatment</keyword>
  <keyword>laser treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

